July 23-24, 2026 Pharmacy Compounding Advisory Committee meeting
FDA advisory committee meeting notice listing multiple peptide bulk substances scheduled for discussion.
Best for muscle recovery
Best Peptides for Muscle Recovery
BPC-157 and TB-500 are the two peptides most frequently discussed in online muscle recovery, injury healing, and performance communities. Both compounds appear in preclinical literature, both are the subject of FDA regulatory scrutiny, and neither is FDA-approved for any indication. This page reviews the public evidence record for each compound and related recovery-oriented peptides, classifies the evidence level, and links to the full compound evidence page. This is an evidence review — not a recommendation, treatment guide, or purchasing resource.
Last reviewed 2026-07-08
Next review 2026-08-07
3 sources
#
Compound
Evidence level
Why it's listed
1
BPC-157
Regulatory watch Primarily animal studies (rat, mouse) and in vitro data; no published human clinical trials BPC-157 is the most discussed peptide in online injury recovery and performance communities. It appears in preclinical literature with reported angiogenic and anti-inflammatory effects, and is scheduled for FDA advisory committee review in July 2026.
Regulatory watch Primarily animal studies (rat, mouse) and in vitro data; no published human clinical trials BPC-157 is the most discussed peptide in online injury recovery and performance communities. It appears in preclinical literature with reported angiogenic and anti-inflammatory effects, and is scheduled for FDA advisory committee review in July 2026.
2
TB-500
Regulatory watch Primarily animal studies and in vitro data on Thymosin Beta-4; limited evidence specific to the TB-500 synthetic fragment; no published human clinical trials TB-500 is a synthetic fragment of Thymosin Beta-4 widely discussed alongside BPC-157 in recovery and performance contexts. Preclinical literature reports effects on cell migration and tissue repair. Also scheduled for FDA advisory committee review in July 2026.
Regulatory watch Primarily animal studies and in vitro data on Thymosin Beta-4; limited evidence specific to the TB-500 synthetic fragment; no published human clinical trials TB-500 is a synthetic fragment of Thymosin Beta-4 widely discussed alongside BPC-157 in recovery and performance contexts. Preclinical literature reports effects on cell migration and tissue repair. Also scheduled for FDA advisory committee review in July 2026.
3
AOD-9604
Regulatory watch Limited published data; early-stage clinical research for metabolic endpoints; no published trials for muscle recovery AOD-9604 appears in online recovery and fat-loss discussions and is sometimes grouped with recovery-oriented peptides. It has a limited published evidence record and no FDA approval.
Regulatory watch Limited published data; early-stage clinical research for metabolic endpoints; no published trials for muscle recovery AOD-9604 appears in online recovery and fat-loss discussions and is sometimes grouped with recovery-oriented peptides. It has a limited published evidence record and no FDA approval.
BPC-157
BPC-157
BPC-157 is the most discussed peptide in online injury recovery and performance communities. It appears in preclinical literature with reported angiogenic and anti-inflammatory effects, and is scheduled for FDA advisory committee review in July 2026.
Evidence level: Primarily animal studies (rat, mouse) and in vitro data; no published human clinical trials
Regulatory status: Not FDA-approved for any indication. Scheduled for discussion at the July 2026 FDA Pharmacy Compounding Advisory Committee (PCAC) meeting. Listed on the FDA bulk drug substances risk list. Sold as research-use-only (RUO); subject to FDA enforcement including warning letters to sellers who market with therapeutic claims or dosing guidance.
Published preclinical research — primarily rat and mouse studies — reports that BPC-157 promotes angiogenesis, modulates inflammatory pathways, and may accelerate healing of tendons, ligaments, muscles, and the gastrointestinal tract. Studies include models of gastric ulcer, muscle crush injury, and tendon-to-bone healing. No published randomized controlled human clinical trials establish efficacy or safety of BPC-157 for any indication. The evidence base is predominantly animal and in vitro.
TB-500
TB-500
TB-500 is a synthetic fragment of Thymosin Beta-4 widely discussed alongside BPC-157 in recovery and performance contexts. Preclinical literature reports effects on cell migration and tissue repair. Also scheduled for FDA advisory committee review in July 2026.
Evidence level: Primarily animal studies and in vitro data on Thymosin Beta-4; limited evidence specific to the TB-500 synthetic fragment; no published human clinical trials
Regulatory status: Not FDA-approved for any indication. Scheduled for discussion at the July 2026 FDA Pharmacy Compounding Advisory Committee (PCAC) meeting. Listed on the FDA bulk drug substances risk list. Sold as research-use-only (RUO); subject to FDA enforcement.
TB-500 is a synthetic fragment of Thymosin Beta-4, a naturally occurring peptide involved in actin sequestration, cell migration, and wound healing. Preclinical and in vitro studies of Thymosin Beta-4 and its fragments report effects on cell migration, angiogenesis, and tissue repair in cardiac, dermal, and corneal injury models. The published literature does not clearly distinguish the evidence base for full-length Thymosin Beta-4 from that of TB-500 as a specific synthetic fragment. No published randomized controlled human clinical trials establish efficacy or safety of TB-500 as a distinct compound for any indication.
AOD-9604
AOD-9604
AOD-9604 appears in online recovery and fat-loss discussions and is sometimes grouped with recovery-oriented peptides. It has a limited published evidence record and no FDA approval.
Evidence level: Limited published data; early-stage clinical research for metabolic endpoints; no published trials for muscle recovery
Regulatory status: Not FDA-approved for any indication. Sold as research-use-only (RUO). Subject to FDA enforcement if marketed with therapeutic claims.
AOD-9604 is a synthetic peptide fragment derived from the C-terminus of human growth hormone (hGH). Published literature includes early-stage clinical research examining metabolic effects, but no published randomized controlled trials establish efficacy for muscle recovery or injury healing. The compound is not FDA-approved and is sold as research-use-only.
Editorial note
This page is an evidence review. It does not recommend any peptide for muscle recovery, injury healing, or any therapeutic purpose. The compounds listed are not FDA-approved. Evidence is predominantly from animal and in vitro studies. Regulatory status is evolving — the July 2026 FDA PCAC meeting may change the compounding and availability landscape for BPC-157 and TB-500. Always consult the full compound evidence page and primary sources before drawing conclusions.
Sources on this page
Source records are stored in the repo and linked from this page.
Certain bulk drug substances for use in compounding may present significant safety risks
FDA page summarizing bulk drug substances that may present significant safety risks in compounding contexts.
Warning Letter: Gram Peptides
FDA warning letter discussing peptide products marketed online and the limits of research-use-only positioning.